Sugammadex: A comprehensive review of the published human science, including renal studies

Parisa Partownavid, Bryan T. Romito, Willy Ching, Ashley A. Berry, Charles T. Barkulis, Kim Ngan P. Nguyen, Jonathan S. Jahr

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Although neuromuscular block (NMB) allows immobility for airway management and surgical exposure, termination of its effect is limited by and associated with side effects of acetylcholinesterase inhibitors. Sugammadex is a selective relaxant binding agent that has been shown to reverse deep NMB, even when administered 3 minutes following a 1.2 mg/kg dose of rocuronium. This novel drug is a modified gamma cyclodextrin, that through encapsulation process terminates the effects of rocuronium and vecuronium (aminosteroid muscle relaxants), and enables the anesthesiologists rapidly to reverse profound NMB induced by rocuronium or vecuronium, in a "can't ventilate, can't intubate" crisis. In this review, data from published phase 1, 2, and 3 clinical trials are reviewed and presented. In addition, clinical trials on special patient populations (patients with pulmonary disease and renal insufficiency) are evaluated. Each article reviewed will conclude with a discussion of relevance, focus on adverse event profile, and clinical usefulness.

Original languageEnglish (US)
Pages (from-to)298-317
Number of pages20
JournalAmerican Journal of Therapeutics
Issue number4
StatePublished - Jan 1 2015


  • cyclodextrins
  • muscle relaxant
  • muscle relaxant reversal
  • rocuronium
  • selective relaxant binding agents
  • sugammadex
  • vecuronium

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Sugammadex: A comprehensive review of the published human science, including renal studies'. Together they form a unique fingerprint.

Cite this